Lipella Pharmaceuticals Brings Oncology Expertise to Advisory Board

Shares in biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) rose nearly 4.0% in intraday trading on Wednesday after the company announced it would expand its Scientific Advisory Board to include oncology expertise.

Dr. Jason Hafron, MD, DDS, PhD, MPH, the Chief Medical Officer at Michigan Institute of Urology, and Professor of Urology at the William Beaumont School of Medicine joins the board, along with Pradeep Tyagi, PhD, MBA, Professor of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA.

Dr. Hafron and Dr. Tyagi bring deep expertise in clinical and translational research in cancer treatment, with a focus on urologic oncology.

Commenting on the appointments, Dr. Michael Chancellor, M.D., Chief Medical Officer of Lipella, said, “I look forward to working with Dr. Hafron and Dr. Tyagi in the advancement of our discovery efforts in the treatment of non-muscle invasive bladder cancer (NMIBC), a disease that affects nearly one million Americans.”

Lipella is developing LP-50 (intravesical pembrolizumab) as a potential treatment for non-muscle invasive bladder cancer (NMIBC). LP-50 offers the potential for increasing efficacy while minimizing systemic toxicity. Lipella has generated preclinical data demonstrating the efficacy of intravesical pembrolizumab in mice, including size-reduction in bladder tumors measured via T2 weighted MRI.


Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Additionally, the company maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. Lipella recently completed an initial public offering in December 2022. For more information, visit or LinkedIn for updates.


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

Lipella Pharmaceuticals Brings Oncology Expertise to Advisory Board

Catie Corcoran

Biotech Editor